Jain, Rakesh
Higa, Sara
Keyloun, Katelyn
Park, Julie
Bonafede, Machaon
Tung, Amy
Gillard, Patrick
Cutler, Andrew J.
Funding for this research was provided by:
AbbVie
Article History
Accepted: 30 May 2022
First Online: 30 June 2022
Declarations
:
: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.
: Rakesh Jain has received grant funding from, or served as a consultant, or on advisory boards and speakers’ bureaus for Addrenex, Alkermes, Allergan (now AbbVie), AstraZeneca, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Rhodes, Supernus, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva, and Tris Pharmaceuticals. Sara Higa is a former employee of AbbVie and may hold AbbVie stock. Patrick Gillard, Katelyn Keyloun, and Amy Tung are employees of AbbVie and may hold stock. Julie Park is an employee of IBM Watson Health, which received funding from Allergan (prior to its acquisition by AbbVie) to conduct this analysis. Machaon Bonafede was an employee of IBM Watson Health at the time the study was conducted and is currently an employee at Veradigm Health, an Allscripts Company. Andrew J. Cutler has been a consultant for AbbVie, Acadia Pharmaceuticals, Akili Interactive, Alfasigma, Alkermes, Avanir, BioXcel Therapeutics, BlackThorn Therapeutics, Intra-Cellular Therapies, Ironshore, Janssen, Karuna Therapeutics, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Relmada Therapeutics, Sage Therapeutics, Sunovion, Supernus Pharmaceuticals, Takeda, Teva, and Tris Pharma; has received speaker/promotional honoraria from AbbVie, Acadia Pharmaceuticals, Alfasigma, Alkermes, Avanir, BioXcel Therapeutics, Corium, Intra-Cellular Therapies, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Takeda, Teva, and Tris Pharma; and has received research grants from Aevi Genomics, Akili Interactive, Alkermes, Allergan (now AbbVie), Arbor Pharmaceuticals, Biohaven, Ironshore, KemPharm, Lilly, Lundbeck, Neos Therapeutics, Novartis, Otsuka, Purdue Canada, Sage Therapeutics, Sunovion, Supernus Pharmaceuticals, Takeda, and Tris Pharma.
: This study was exempt from ethics committee approval and institutional review because it is a retrospective analysis that used anonymized and de-identified data certified as fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Allergan (prior to its acquisition by AbbVie) obtained permission to access and use the IBM<sup>®</sup> MarketScan<sup>®</sup> data used in the analysis through licensing agreements.
: Not applicable.
: Not applicable.
: Data that support the findings of this study were used under license from IBM<sup>®</sup> Watson Health<sup>TM</sup>. Restrictions apply to the availability of these data, which are not publicly available and cannot be shared.
: Not applicable.
: AC, RJ, MB, JP, PG, KK, AT, and SH were involved with the study design, analysis, and/or interpretation of the data. MB and JP also performed statistical analyses. All authors contributed to and have approved the final manuscript and are accountable for all aspects of the work, as well as the ability to identify their individual unique contributions and to ensure the integrity of their contributions.